Amgen publishes study assessing cost-effectiveness of Repatha; Brilinta reduces death in patients with heart-attack history; Roche drug gets priority review
Five things for pharma marketers to know: Wednesday, June 21, 2017
Insurance companies balk at expensive PCSK9 inhibitors; Publicis to focus investments on AI platform; clinical trial reveals Novartis’ eye drug requires less frequent injections
Five things for pharma marketers to know: Friday, June 16, 2017
The FDA delays final rule related to off-label use; Amgen’s Repatha reduces risk of death by 20%, study finds; FDA rejects AstraZeneca’s hyperkalaemia drug
Five things for pharma marketers to know: Monday, March 13, 2017
Court to allow Sanofi and Regeneron to market Praluent during appeal; Xarelto is effective in treating artery disease; VP advocates for right-to-try laws
Five things for pharma marketers to know: Friday, February 3, 2017
Trial finds that Repatha reduces risk of heart attack and stroke; California measure would ban drug coupons in some cases; Takeda to limit price increases
When it comes to PCSK9s, payers resisted — and sales flopped
The first two PCSK9s landed with a thud. What does their disappointing launch say about the need for marketers of CV drugs to get their pricing houses in order?
